Shuangyue Y. Li

Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

Published: October 26, 2024

High Expression of GPR183 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia.

Journal: Biochemical genetics

Published: October 09, 2024

A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting.

Journal: Discover oncology

Published: August 10, 2024

High expression of EBP is an adverse prognostic factor for de novo acute myeloid leukemia.

Journal: Hematology (Amsterdam, Netherlands)

Published: August 01, 2024

Clinicopathologic spectrum and outcomes of primary ovarian lymphoma: a retrospective case series.

Clinicopathologic spectrum and outcomes of primary ovarian lymphoma: a retrospective case series.

A prospective, multicenter study on stem cell mobilization using the EAP regimen as first-line mobilization in patients with multiple myeloma and lymphoma.

A prospective, multicenter study on stem cell mobilization using the EAP regimen as first-line mobilization in patients with multiple myeloma and lymphoma.

Successful Treatment of Primary Poor Graft Function After Haploidentical Hematopoietic Stem Cell Transplantation With Low-Dose Decitabine Followed by Donor Lymphocyte Infusion and Eltrombopag.

Successful Treatment of Primary Poor Graft Function After Haploidentical Hematopoietic Stem Cell Transplantation With Low-Dose Decitabine Followed by Donor Lymphocyte Infusion and Eltrombopag.

Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine.

Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine.

Hematopoietic progenitor kinase 1 inhibitor BGB-15025 induces apoptosis in acute myeloid leukemia cells through the cell cycle pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway signaling axis.

Hematopoietic progenitor kinase 1 inhibitor BGB-15025 induces apoptosis in acute myeloid leukemia cells through the cell cycle pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway signaling axis.

Precision prediction of venetoclax-azacitidine treatment efficacy in acute myeloid leukemia via integrative drug screening and machine learning.

Precision prediction of venetoclax-azacitidine treatment efficacy in acute myeloid leukemia via integrative drug screening and machine learning.

Efficacy and safety of etoposide + cytarabine + pegfilgrastim mobilization regimen versus G-CSF mobilization regimen alone for hematopoietic stem cell mobilization in patients with multiple myeloma and lymphoma.

Efficacy and safety of etoposide + cytarabine + pegfilgrastim mobilization regimen versus G-CSF mobilization regimen alone for hematopoietic stem cell mobilization in patients with multiple myeloma and lymphoma.

Venetoclax combined with azacitidine in elderly acute myeloid leukemia: A retrospective comparison of 14-day vs 28-day dosing regimens.

Venetoclax combined with azacitidine in elderly acute myeloid leukemia: A retrospective comparison of 14-day vs 28-day dosing regimens.

Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma.

Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma.

High Expression of GPR183 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia.

High Expression of GPR183 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia.

A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting.

A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting.

High expression of EBP is an adverse prognostic factor for de novo acute myeloid leukemia.

High expression of EBP is an adverse prognostic factor for de novo acute myeloid leukemia.

Efficacy and safety of etoposide + cytarabine + pegfilgrastim mobilization regimen versus G-CSF mobilization regimen alone for hematopoietic stem cell mobilization in patients with multiple myeloma and lymphoma.

Efficacy and safety of etoposide + cytarabine + pegfilgrastim mobilization regimen versus G-CSF mobilization regimen alone for hematopoietic stem cell mobilization in patients with multiple myeloma and lymphoma.

Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma.

Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma.